Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22012098 | 0.80 | PARP1 (0.37) | — | |
| SCHEMBL3071652 | 0.77 | — | — | |
| SCHEMBL6944904 | 0.77 | CYP1A2 (0.51) | CYP1A2CYP2C9CYP2D6CYP2C19HIF1A | |
| SCHEMBL24992268 | 0.77 | DRD2 (0.46) | DRD2 | |
| SCHEMBL1438023 | 0.75 | MAP3K14 (0.53) | DRD2MAP3K14 | |
| SCHEMBL17397762 | 0.75 | P2RX7 (0.37) | ANPEP | |
| SCHEMBL4643692 | 0.75 | ALDH1A1 (0.38) | ANPEPCYP1A2CYP2C9TSHR | |
| SCHEMBL18986893 | 0.75 | P2RX7 (0.37) | ANPEP | |
| SCHEMBL19953487 | 0.75 | DRD2 (0.41) | CYP11B1CYP11B2DRD2DRD3ANPEP | |
| SCHEMBL18204541 | 0.75 | HTR2C (0.45) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077989-A1 | CYCLIC IMIDATE LIGANDS | UNIVERSITEIT GENT (BE) | 2012-03-29 | — | — | US | disclosed |
| EP-2416879-A1 | CYCLIC IMIDATE LIGANDS | Universiteit Gent (BE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115903-A1 | CYCLIC IMIDATE LIGANDS | UNIVERSITEIT GENT (BE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077989-A1 | CYCLIC IMIDATE LIGANDS | IDH2, CYCS, NAPRT | CYP11B1 2238/4885CYP11B2 2013/4885DRD2 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.